# Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

> **NCT03116594** · PHASE2,PHASE3 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 675 (actual)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** NBP608
- **BIOLOGICAL:** Zostavax

## Key facts

- **NCT ID:** NCT03116594
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-03
- **Primary completion:** 2014-04-08
- **Final completion:** 2015-03-07
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2017-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03116594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03116594, "Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03116594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*